Physician profile
Daniel Sackett
NPI 1952510372
$993.93
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $300 · 2021: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $368.64 | 2019-2021 | |
| Abbvie INC. | $74.28 | 2019-2020 | |
| Axogen | $63.98 | 2020 | |
| Janssen Biotech, INC. | $56.07 | 2019 | |
| Dendreon Pharmaceuticals LLC | $53.04 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $52.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.38 | 2019-2020 | |
| Medtronic, INC. | $35.64 | 2021 | |
| Ferring Pharmaceuticals INC. | $31.68 | 2019 | |
| Pfizer INC. | $29.88 | 2019 | |
| Endo Pharmaceuticals INC. | $28.31 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $26.11 | 2020 | |
| Myovant Sciences INC. | $23.34 | 2021 | |
| Blue Earth Diagnostics | $19.63 | 2021 | |
| Boston Scientific Corporation | $17.86 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17.45 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.68 | 2020 | |
| Coloplast Corp | $13.25 | 2019 | |
| Antares Pharma, INC. | $13.18 | 2019 | |
| Photocure INC | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.